RegMed XB stands for Regenerative Medicine Crossing Borders. It is a institute of Dutch and Flemish public (universities and governments) and private (health foundations and companies) partners that work together to develop regenerative medicine solutions to health challenges. RegMed XB works on providing regenerative solutions. Next to that, the RegMed XB Pilot Factory makes it possible to execute scaling steps towards GMP grade product. We believe that when researchers and entrepreneurs work side by side, we stand the best chance to bring the most impact to patients and society at large.
| Website | http://www.regmedxb.com |
| Revenue | $24.1 million |
| Employees | 27 (16 on RocketReach) |
| Founded | 2016 |
| Phone | +31 6 40615546 |
| Technologies |
JavaScript
,
HTML
,
PHP
+10 more
(view full list)
|
| Industry | Research Services |
| Keywords | Regenerative Medicine, Cell Therapy, Regenerative Therapies, Tissue Engineering, Stem Cell Research, Translational Research, Advanced Therapies, Biomedical Research, Biotechnology, Biomaterials, Drug Development, Pharmaceutical Research, Life Sciences, Clinical Trials, Academic Research, Scientific Research, Health Innovation, Medical Technology, Healthcare |
| Competitors | Amgen, Acuity Insurance, Organogenesis, AlloSource®, AVITA Medical, Mesoblast Limited, Pluristem Therapeutics, Lilly India, Sernova Corp., StemCells, Inc. +35 more (view full list) |
Looking for a particular RegMed XB employee's phone or email?
The RegMed XB annual revenue was $24.1 million in 2026.
Bernard Mulder is the General Director of RegMed XB.
16 people are employed at RegMed XB.